tetano
Editor, Senior Moderator
In Vivo
. 2024 Nov-Dec;38(6):2853-2863.
doi: 10.21873/invivo.13766. Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19
Lívia DE Oliveira Sales[SUP] #[/SUP][SUP] 1 [/SUP], Jean Breno Silveira DA Silva[SUP] #[/SUP][SUP] 2 [/SUP], Flávia Melo Cunha DE Pinho Pessoa[SUP] 1 [/SUP], Beatriz Maria Dias Nogueira[SUP] 1 [/SUP], Lais Lacerda Brasil DE Oliveira[SUP] 1 [/SUP], André Salim Khayat[SUP] 3 [/SUP], Manoel Odorico DE Moraes Filho[SUP] 1 [/SUP], Maria Elisabete Amaral DE Moraes[SUP] 1 [/SUP], Raquel Carvalho Montenegro[SUP] 1 [/SUP], Caroline Aquino Moreira-Nunes[SUP] 4 2 3 [/SUP]
Affiliations
Background/aim: SARS-CoV-2 infection presents different severity levels that suggest the influence of genetic factors on the clinical outcome of the disease. In cases of severe COVID-19, the presence of elevated coagulation markers, increased platelet activation and aggregation and the risk of thrombotic complications are described. Given the participation of these cells in several serious viral infections and their negative role when associated with a prothrombotic response, it is important to understand the mechanistic role of SARS-CoV-2 in platelet physiology. This study evaluated the hyperexpression of platelet-activating factor receptor (PTAFR) and platelet factor 4 (PF4) in unvaccinated and hospitalized patients with COVID-19.
Patients and methods: The study included 43 COVID-19 patients stratified according to WHO guidelines. Subsequently, the expression of the PTAFR and PF4 genes were evaluated using the real-time quantitative PCR and their possible correlation with the severity of the disease and clinical variables including hospitalization, outcome, sex, age and laboratory parameters (platelet count, INR and D-dimer).
Results: The analysis demonstrated a significant (p<0.05) hyperexpression of these genes COVID-19 patients (n=43) compared to healthy controls. Expression of these genes in patients was not statistically significant (p>0.05) different between patients stratified according to clinical variables.
Conclusion: The expression of PTAFR and PF4 suggests an important molecular pathway in the pathophysiology of the disease and may be valuable platelet biomarkers to indicate increased risk in patients with COVID-19 who require hospital care, contributing to personalized intervention strategies and improving their clinical management.
Keywords: COVID-19; PF4; PTAFR; platelet biomarkers; platelets.
. 2024 Nov-Dec;38(6):2853-2863.
doi: 10.21873/invivo.13766. Hyperexpression of PTAFR and PF4 as Possible Platelet Risk Biomarkers in Patients With COVID-19
Lívia DE Oliveira Sales[SUP] #[/SUP][SUP] 1 [/SUP], Jean Breno Silveira DA Silva[SUP] #[/SUP][SUP] 2 [/SUP], Flávia Melo Cunha DE Pinho Pessoa[SUP] 1 [/SUP], Beatriz Maria Dias Nogueira[SUP] 1 [/SUP], Lais Lacerda Brasil DE Oliveira[SUP] 1 [/SUP], André Salim Khayat[SUP] 3 [/SUP], Manoel Odorico DE Moraes Filho[SUP] 1 [/SUP], Maria Elisabete Amaral DE Moraes[SUP] 1 [/SUP], Raquel Carvalho Montenegro[SUP] 1 [/SUP], Caroline Aquino Moreira-Nunes[SUP] 4 2 3 [/SUP]
Affiliations
- PMID: 39477442
- DOI: 10.21873/invivo.13766
Background/aim: SARS-CoV-2 infection presents different severity levels that suggest the influence of genetic factors on the clinical outcome of the disease. In cases of severe COVID-19, the presence of elevated coagulation markers, increased platelet activation and aggregation and the risk of thrombotic complications are described. Given the participation of these cells in several serious viral infections and their negative role when associated with a prothrombotic response, it is important to understand the mechanistic role of SARS-CoV-2 in platelet physiology. This study evaluated the hyperexpression of platelet-activating factor receptor (PTAFR) and platelet factor 4 (PF4) in unvaccinated and hospitalized patients with COVID-19.
Patients and methods: The study included 43 COVID-19 patients stratified according to WHO guidelines. Subsequently, the expression of the PTAFR and PF4 genes were evaluated using the real-time quantitative PCR and their possible correlation with the severity of the disease and clinical variables including hospitalization, outcome, sex, age and laboratory parameters (platelet count, INR and D-dimer).
Results: The analysis demonstrated a significant (p<0.05) hyperexpression of these genes COVID-19 patients (n=43) compared to healthy controls. Expression of these genes in patients was not statistically significant (p>0.05) different between patients stratified according to clinical variables.
Conclusion: The expression of PTAFR and PF4 suggests an important molecular pathway in the pathophysiology of the disease and may be valuable platelet biomarkers to indicate increased risk in patients with COVID-19 who require hospital care, contributing to personalized intervention strategies and improving their clinical management.
Keywords: COVID-19; PF4; PTAFR; platelet biomarkers; platelets.